Improving Care of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Participation in activities of daily life can be challenging for those with transthyretin amyloid cardiomyopathy (ATTR-CM), a restrictive cardiomyopathy produced by extracellular deposition of transthyretin. Geographic and racial healthcare disparities add to the burden of disease. Shared decision making and early detection with readily available noninvasive tests, among other strategies, are essential as therapy for ATTR-CM.
Videos On Demand
Recognize the Complexities of Transthyretin Amyloidosis (ATTR amyloidosis)
The clinical presentation of ATTR may be hidden in plain sight. In these continuing education activities explore the varied clinical presentations of amyloidosis in different organ systems including the heart, nervous system, gastro-intestinal tract, and kidneys. Get the facts from an expert panel on how to recognize and treat the complexities of this progressive, degenerative, and multisystemic disorder.
Resources for Clinicians
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Circulation
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging
Circulation: Cardiovascular Imaging
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2—Diagnostic Criteria and Appropriate Utilization
Circulation: Cardiovascular Imaging
This activity is supported by an independent educational grant from Pfizer.